Windlas Biotech Limited — Others, 09-01-2025: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Windlas Biotech Limited has announced a board meeting to discuss the financial results for the quarter and half-year ended December 31, 2024. Additionally, the company provided a certificate confirming that no demat requests were processed during the quarter, as all shares are held in electronic form.

This update indicates stable operational procedures and adherence to compliance protocols, which can reinforce investor confidence. The absence of demat requests further highlights the streamlined structure of the company's shareholding, potentially portraying a steady shareholder base. Investors may view this positively, reflecting operational effectiveness and stability in governance.